BGC > Product Search > Raxatrigine

Description :
Raxatrigine is a novel analgesic for the treatment of lumbosacral radiculopathy (sciatica) and trigeminal neuralgia. It acts as a selective, small-molecule, state-dependent Nav1.7 voltage-gated sodium channel blocker. It is a peripherally and centrally acting agent that inhibits sodium channels in a state-dependent fashion. It shows selectivity for the Nav1.7 subtype over the other subtypes tested for both the resting and depolarized states. It was developed by Convergence Pharmaceuticals. It received orphan-drug designation from the US Food and Drug Administration in July 2013. It is currently in phase II studies in bipolar depression.

• Molecular Weight :314.35
• Boiling Point :529.5±50.0 °C | Condition: Press: 760 Torr
• Purity :> 98%

Molecular Formula :
C18H19FN2O2
Canonical SMILES :
O=C(N)[C@H]1N[C@@H](C2=CC=C(OCC3=CC=CC=C3F)C=C2)CC1
InChI :
1S/C18H19FN2O2/c19-15-4-2-1-3-13(15)11-23-14-7-5-12(6-8-14)16-9-10-17(21-16)18(20)22/h1-8,16-17,21H,9-11H2,(H2,20,22)/t16-,17+/m1/s1
InChIKey :
JESCETIFNOFKEU-SJORKVTESA-N
Solubility :
10 mM in DMSO
Appearance :
Solid powder
Application :
Raxatrigine is a novel analgesic for the treatment of lumbosacral radiculopathy (sciatica) and trigeminal neuralgia. It received orphan-drug designation from the US Food and Drug Administration in July 2013.
Storage : -20°C Freezer
Synonyms :
(2S,5R)-5-(4-((2-fluorobenzyl)oxy)phenyl)pyrrolidine-2-carboxamide; GSK1014802; GSK 1014802; GSK-1014802; CNV1014802; CNV-1014802; CNV 1014802; Raxatrigine

More details are to be found here